Lycia Therapeutics, Inc. SEC filings LYCA
Lycia Therapeutics, Inc. has 40 filings in SEC EDGAR's recent list, going back to Mar 17, 2020. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Oct 23, 2026 | — |
| 424B4 | Prospectus | Oct 23, 2026 | — |
| S-1MEF | Filing | Oct 22, 2026 | — |
| S-1/A | Amended registration statement | Oct 20, 2026 | — |
| S-1 | Registration statement | Oct 5, 2026 | — |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LYCA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC CIK
- 1806540
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.